Amgen, Inc. Hits New 52-Week High of USD 397.89

Amgen, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 397.89 on July 28, 2026. This achievement underscores the company's robust performance, particularly in the context of its impressive one-year performance of 29.0%, significantly outpacing the S&P 500's return of 16.26%. With a market capitalization of USD 188,011 million, Amgen is classified as a large-cap company, reflecting its substantial presence in the market. The stock's price-to-earnings (P/E) ratio stands at 22.00, indicating a solid valuation relative to its earnings. Additionally, the company boasts a commendable return on equity of 100.80%, showcasing its efficiency in generating profits from shareholders' equity. Amgen also offers a dividend yield of 2.04%, appealing to income-focused investors. The company's debt-to-equity ratio of 5.27 suggests a conservative approach to leveraging, further solidifying its financial stability. Overall, Amgen's recent performance and key financial metrics highlight its strong position within the industry.